Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

Urology

Volumn 59, Issue 1, 2002, Pages 73-78

  Benaim, Elie A ^a   Pace, Christopher M ^a   Lam, Po M ^a   Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; MULTIPLE REGRESSION; ORCHIECTOMY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; RETROSPECTIVE STUDY; SCORING SYSTEM; TIME;

AGED; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ODDS RATIO; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036143005     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01440-6     Document Type: Article

References (12)

1. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
2. Clinical use of prostate specific antigen in patients with prostate cancer
3. Prostate cancer trends in the PSA era; data from the SEER program
4. Treatment options for prostate cancer; part 1-stage, grade, PSA, and changes in the 1990s
5. Nonparametric estimation from incomplete observations
6. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer; analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853
7. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
8. Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer
9. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization
10. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer
11. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer
12. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer